ライフサイエンスコーパス: fluconazole

1 ricin with flucytosine, or amphotericin with fluconazole).

2 buprofen) to not degradable (chlorthalidone, fluconazole).

3 s ranged from 96.9% (voriconazole) to 98.6% (fluconazole).

4 ted alanine transaminase (4 caspofungin vs 8 fluconazole).

5 ial; 26 were treated with Sb(v), and 27 with fluconazole.

6 athogens that are intrinsically resistant to fluconazole.

7 ients treated with either an echinocandin or fluconazole.

8 ing the most commonly prescribed antifungal, fluconazole.

9 ncluding potassium iodide, itraconazole, and fluconazole.

10 n antifungal therapy with amphotericin B and fluconazole.

11 ucytosine, and $44 605 for amphotericin plus fluconazole.

12 clinical and radiological response plus oral fluconazole.

13 ays for sequestration of the antifungal drug fluconazole.

14 days, followed by consolidation therapy with fluconazole.

15 exhibited >/=4-fold increases in the MICs to fluconazole.

16 es) and 44 isolates of C. neoformans against fluconazole.

17 unds that synergize with the antifungal drug fluconazole.

18 -resistant Candida albicans to the effect of fluconazole.

19 mphotericin B deoxycholate, flucytosine, and fluconazole.

20 8% of C. glabrata isolates were resistant to fluconazole.

21 cally (decrease efficacy) when combined with fluconazole.

22 Five survivors were known to have received fluconazole.

23 , L-NMMA, and, to a larger extent, by L-NMMA+fluconazole.

24 resistant or dose-dependently susceptible to fluconazole.

25 inhibits nutrient intake when combined with fluconazole.

26 1, which encodes an efflux pump that exports fluconazole.

27 eningitis over 3 months of follow-up without fluconazole.

28 pathogen, increasing their susceptibility to fluconazole.

29 ce of the latter to a widely used antifungal fluconazole.

30 n Candida glabrata against anidulafungin and fluconazole.

31 tion (r) of zone diameters was strongest for fluconazole (0.69) and amphotericin (0.70) and moderate

32 earson correlation of MICs was strongest for fluconazole (0.94) and caspofungin (0.88).

33 With fluconazole 1200 mg/d therapy, 68% of meningitis patient

34 All patients also received oral fluconazole 1200 mg/day for 14 days.

35 cribed drug (260 patients [50%]) followed by fluconazole (148 [29%]) and itraconazole (93 [18%]).

36 ily (b.i.d.) for 3 days, or a single dose of fluconazole 150 mg (current FDA-approved dose to treat a

37 in MICs obtained by Etest was determined for fluconazole (21 isolates), voriconazole (28 isolates), a

38 %), topical amphotericin B (1mg/ml), topical fluconazole (2mg/ml) and oral ketoconazole (200mg).

39 mpairment did not differ between the groups (fluconazole, 31% [95% CI, 21%-41%] vs placebo, 27% [95%

40 ak points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocand

41 Cs) for amphotericin B (2.6 +/- 3.5 mug/mL), fluconazole (36.9 +/- 30.7 mug/mL), and voriconazole (1.

42 fixed-dose combination tablet), 12 weeks of fluconazole, 5 days of azithromycin, and a single dose o

43 Fluconazole (6 mg/kg of body weight) or placebo.

44 the efficacy and safety of high-dosage oral fluconazole (6.5-8.0 mg/kg/d for 28 days) versus a stand

45 tifungal therapy consisted of monotherapy of fluconazole (60%), caspofungin (24%), voriconazole (8%),

46 00 mg daily); group 3, AmB (0.7-1 mg/kg) and fluconazole (600 mg twice daily); and group 4, AmB (0.7-

47 times daily); group 2, AmB (0.7-1 mg/kg) and fluconazole (800 mg daily); group 3, AmB (0.7-1 mg/kg) a

48 mg per kilogram of body weight per day) and fluconazole (800 mg per day) for 14 days, followed by co

49 g/day) for 2 weeks; and (3) amphotericin and fluconazole (800 mg/day) for 2 weeks.

50 AmB plus fluconazole (800-1200 mg/day) represents an immediately

51 ed altered sphingolipid content and elevated fluconazole accumulation compared with the wild type.

52 Furthermore, azoffluxin enhances fluconazole activity in mice infected with C. auris, red

53 Azoffluxin enhances fluconazole activity through the inhibition of efflux pu

54 frontline beta-lactam antibiotics antagonize fluconazole activity.

55 toxic effects, were considered as potential fluconazole adjuvants and thus were termed as "repositio

56 indolinone (azoffluxin) that synergizes with fluconazole against C. auris.

57 Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%)

58 l hits were able to act synergistically with fluconazole against the test strain.

59 Fluconazole also reduced urinary output in tolvaptan-tre

60 ested whether treatment with the fungistatic fluconazole ameliorated the adverse intestinal outcome o

61 Exposure to fluconazole, an antimicrobial drug that targets ergoster

62 linear, rigid core and 3-nitrotriazole-based fluconazole analogues were synthesized as dual functioni

63 zole susceptibility is strain-dependent, and fluconazole and 5-fluorocytosine are not active.

64 .4% (95% CI, 11.6%-34.4%) without preemptive fluconazole and 5.7% (95% CI, 3.0%-9.7%) with preemptive

65 s after treatment) of 22.2% (6 of 27) in the fluconazole and 53.8% (14 of 26) in the Sb(v) group (P =

66 rence in EFA between AmB in combination with fluconazole and AmB plus 5-FC for the treatment of HIV-a

67 Combinations of 12f with fluconazole and amphotericin B at subinhibitory concentr

68 s that are resistant to the antifungal drugs fluconazole and amphotericin B.

69 a glabrata) were multidrug resistant to both fluconazole and an echinocandin.

70 The EA was lower for fluconazole and C. neoformans at 86.4%.

71 reference and Vitek 2 MICs was observed for fluconazole and Candida species (94.0%).

72 zole resistance rates were low; however, the fluconazole and echinocandin coresistance among C. glabr

73 th Asia clade I with intrinsic resistance to fluconazole and elevated MIC to voriconazole (81%), amph

74 r with dimethyl sulfoxide as the solvent for fluconazole and flucytosine impacted the in vitro potenc

75 ity of 24% (95% CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortal

76 sensitivity using rats exposed to fungicide (fluconazole and nystatin).

77 at were resistant to fluconazole between the fluconazole and placebo groups.

78 , reduces the number of infants treated with fluconazole and the duration of fluconazole therapy for

79 to strains of C. glabrata resistant to both fluconazole and the echinocandins are of concern and pro

80 with the binding interactions observed with fluconazole and the natural substrate dicyclotyrosine.

81 MG improved growth in the presence of fluconazole and this was largely Mrr1-dependent with con

82 -spectrum synergistic interactions with both fluconazole and voriconazole against ~89% of the tested

83 solates were fluconazole resistant in vitro, fluconazole and voriconazole exhibited significantly hig

84 lture bottles is a rapid and easy method for fluconazole and voriconazole susceptibility testing for

85 e and tioconazole, and to the triazole drugs fluconazole and voriconazole.

86 flow-mediated dilatation was not affected by fluconazole and was reduced by L-NMMA and L-NMMA+flucona

87 inhibitors of cytochrome P450 epoxygenases (fluconazole) and NO synthase (N(G)-monomethyl-l-arginine

88 le), respiratory failure (6 caspofungin vs 9 fluconazole), and elevated alanine transaminase (4 caspo

89 rtant for other stressors such as rapamycin, fluconazole, and hydroxyurea treatment.

90 tibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species an

91 ut its effect on mortality and the safety of fluconazole are unknown.

92 eviously, we identified the antimycotic drug fluconazole as a potential modulator of AQP2 localizatio

93 Last, we identified the fungicide fluconazole as an inhibitor of cAMP-mediated redistribut

94 lumbar puncture before initiating preemptive fluconazole at 800 mg/d further reduced the incidence of

95 Oral fluconazole at a dosage of 6.5-8 mg/kg/d for 28 days sho

96 Oral fluconazole at a dosage of 6.5-8 mg/kg/d for 28 days sho

97 , and those in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 weeks.

98 The involvement of these pathways in fluconazole basal tolerance was associated with sphingol

99 kinase activity of Ypk1 are required for the fluconazole basal tolerance.

100 x 10(9) cells/L; OR, 8.7; 95% CI, 2.5-30.2), fluconazole-based induction treatment, and slow clearanc

101 on of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups.

102 heating in controls (an effect diminished by fluconazole) but not in patients.

103 s for categorical agreement were highest for fluconazole by disk diffusion (0.902, standard error [SE

104 rine lactone, induces candidal resistance to fluconazole by reversing the antifungal's effect on the

105 Therapeutic drug monitoring of fluconazole can be a valuable tool to detect possible un

106 ncentrations of 3 commonly used antifungals: fluconazole, caspofungin, and amphotericin B.

107 s rapidly fungicidal against blastospores of fluconazole/caspofungin resistant C. albicans strains, a

108 For less common species without fluconazole CBPs, the epidemiological cutoff values (ECV

109 KKY101 cells led to higher fungal load after fluconazole challenge than wild-type cells.

110 aled pitavastatin displaying the most potent fluconazole chemosensitizing activity against the test s

111 Additionally, the pitavastatin-fluconazole combination significantly reduced the biofil

112 events was similar for infants who received fluconazole compared with placebo.

113 onally, we assessed the relation between the fluconazole concentration and the time to culture conver

114 The fluconazole concentration is not sufficient in pediatric

115 A higher fluconazole concentration was associated with a shorter

116 The fluconazole concentration was considered subtherapeutic

117 e correlation of clinical variables with the fluconazole concentration.

118 om January 2007 to October 2013 and for whom fluconazole concentrations were available.

119 In contrast, fluconazole did not bind to CYP5218, voriconazole and ke

120 3]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% CI, 80.96-195.97]);

121 One patient treated with fluconazole discontinued treatment owing to malaise, hea

122 he fluconazole trough concentration with the fluconazole dose (P <.001), weight (P = .009), and the s

123 ently recommended dose regimen, and a higher fluconazole dose is required to achieve adequate drug ex

124 d (O2M) to identify drugs that interact with fluconazole, either increasing or decreasing efficacy.

125 tetralogy of Fallot was observed (7 cases in fluconazole-exposed pregnancies [prevalence, 0.10%] as c

126 efects overall (210 birth defects among 7352 fluconazole-exposed pregnancies [prevalence, 2.86%] and

127 From a cohort of 1,405,663 pregnancies, oral fluconazole-exposed pregnancies were compared with up to

128 The majority of fluconazole-exposed pregnancies were in women who receiv

129 risk of spontaneous abortion associated with fluconazole exposure (HR, 1.48; 95% CI, 1.23-1.77).

130 There was no significant association between fluconazole exposure and stillbirth (HR, 1.32 [95% CI, 0

131 n Denmark, we evaluated first-trimester oral fluconazole exposure and the risk of birth defects overa

132 In monospecies biofilms, fluconazole exposure favored growth of C. glabrata and C

133 Fluconazole exposure may confer an increased risk of tet

134 In addition, oral fluconazole exposure was not associated with a significa

135 Oral fluconazole exposure was not associated with an increase

136 The extensive use of fluconazole (FLC) and other azole drugs has caused the e

137 -Saharan Africa, where most patients receive fluconazole (FLC) monotherapy.

138 In this study, we performed a series of fluconazole (FLC) perturbation experiments for two T. as

139 Fluconazole (FLC) resistance is common in C. glabrata an

140 gal synergy of C12 and C14 with four azoles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS

141 0 generations) exhibited higher tolerance to fluconazole (FLC), micafungin, 5- flucytosine and amphot

142 (ANF), caspofungin (CSF), micafungin (MCF), fluconazole (FLC), posaconazole (PSC), and voriconazole

143 wever, 50% of isolates that are resistant to fluconazole (FLC), the most widely used antifungal, are

144 reatment for Africa (ACTA) trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effectiv

145 lucytosine for at least 2 weeks, followed by fluconazole for a minimum of 8 weeks.

146 y-betaNM) is superior to the antifungal drug fluconazole for all three strains examined.

147 cies-specific clinical breakpoints (CBPs) of fluconazole for Candida (Vitek 2 AF03 yeast susceptibili

148 tococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.

149 nical cryptococcal meningitis and preemptive fluconazole for those without meningitis.

150 amphotericin-B for those with CNS disease or fluconazole for those without.

151 sting results, we caution against the use of fluconazole for treating C. quercitrusa infections.

152 Nineteen trials (10 with fluconazole, four with ketoconazole, one with itraconazo

153 Among 3315 women exposed to oral fluconazole from 7 through 22 weeks' gestation, 147 expe

154 Among 5382 women exposed to fluconazole from gestational week 7 to birth, 21 experie

155 tudy of critically ill children treated with fluconazole from January 2007 to October 2013 and for wh

156 candidiasis occurred less frequently in the fluconazole group (3% [95% CI, 1%-6%]) vs the placebo gr

157 1161 600 mg b.i.d. (78.6%) groups versus the fluconazole group (62.5%); differences were not statisti

158 in group vs 7.2% (95% CI, 4.4%-11.8%) in the fluconazole group (overall P = .03 by log-rank test) and

159 ps versus 28.5% and 46.1% of subjects in the fluconazole group, respectively, had evidence of mycolog

160 quencies of adverse effects in the Sb(v) and fluconazole groups were similar, 34.6% versus 37% respec

161 herapeutic cure at Day 28 in the VT-1161 and fluconazole groups.

162 Combination therapy with fluconazole had no significant effect on survival, as co

163 The fluconazole hypersensitivity phenotype of these mutants,

164 h timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitorin

165 gen (CrAg) screening and targeted preemptive fluconazole in antiretroviral-naive human immunodeficien

166 ot support the universal use of prophylactic fluconazole in extremely low-birth-weight infants.

167 ation are available, cautious prescribing of fluconazole in pregnancy may be advisable.

168 ionwide cohort study in Denmark, use of oral fluconazole in pregnancy was associated with a statistic

169 omized, blinded, placebo-controlled trial of fluconazole in premature infants.

170 ed the efficacy and safety of VT-1161 versus fluconazole in subjects with moderate-to-severe acute VV

171 r results suggest posaconazole could replace fluconazole in the treatment of PAM.

172 urther improved the therapeutic potential of fluconazole in vivo.

173 e fungal disease events (6 caspofungin vs 17 fluconazole) included 14 molds, 7 yeasts, and 2 fungi no

174 In mice, fluconazole increased collecting duct AQP2 plasma membra

175 Fluconazole increased plasma membrane localization of AQ

176 In isolated mouse collecting ducts, fluconazole increased transepithelial water reabsorption

177 focus in very low birth weight infants, with fluconazole increasingly used as prophylaxis.

178 All 738 subjects received amphotericin + fluconazole induction therapy and had serial quantitativ

179 Nine patients receiving fluconazole induction therapy were reinduced with AMB pl

180 Presumed susceptibility to oral fluconazole, intravenous amphotericin B, intravitreal am

181 Fluconazole is approved by the US Food and Drug Administ

182 irst-line treatment for pregnant women, oral fluconazole is often used despite limited safety informa

183 Fluconazole is recommended as first-line treatment in in

184 The azole class antifungal, fluconazole, is widely available and has multi-species a

185 Clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole an

186 s for severe or disseminated disease include fluconazole, itraconazole, or amphotericin; newer triazo

187 als (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazol

188 ; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, o

189 uced flow-mediated dilatation was reduced by fluconazole, L-NMMA, and, to a larger extent, by L-NMMA+

190 lux pump Cdr1, thus increasing intracellular fluconazole levels.

191 inclusion criteria, reporting comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconaz

192 gin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) p

193 Fluconazole MICs of >/=64 mug/ml were considered resista

194 Therefore, fluconazole monotherapy is widely used in low-income and

195 Fluconazole monotherapy was suboptimal despite Cryptococ

196 However, with widely used fluconazole monotherapy, mortality because of HIV-relate

197 to prophylaxis with caspofungin (n = 257) or fluconazole (n = 260).

198 ultivariable analysis, among HSCT recipients fluconazole nonsusceptibility was independently associat

199 or amphotericin B use; among SOT recipients, fluconazole nonsusceptibility was independently associat

200 tal of 162 isolates (9.7%) were resistant to fluconazole, of which 98.8% were nonsusceptible to voric

201 We assessed the influence of fluconazole on AQP2 localization in vitro and in vivo as

202 nt role in managing stress exerted either by fluconazole or by the host environment.

203 Routine prophylaxis with fluconazole or L-AmB reduces the incidence of IFI follow

204 tes were randomly assigned to receive either fluconazole or placebo twice weekly for 42 days.

205 t reduction in the rate of IFI was seen with fluconazole (OR 0.21, CI 0.06-0.57) and L-AmB (OR 0.21,

206 caspofungin vs 3.1% (95% CI, 1.4%-6.9%) with fluconazole (overall P = .046 by log-rank test).

207 overall survival (68.8% caspofungin vs 70.8% fluconazole, overall P = .66 by log-rank test) were obse

208 tifungal therapy (71.9% caspofungin vs 69.5% fluconazole, overall P = .78 by log-rank test) or 2-year

209 echinocandin and in 15 (17.1%) treated with fluconazole (P = .730).

210 ic yeast Candida albicans during exposure to fluconazole plus a calcineurin inhibitor, suggesting tha

211 e, and the alternative therapy is 2 weeks of fluconazole plus flucytosine.

212 was compared with CLSI BMD method M27-A3 for fluconazole, posaconazole, and voriconazole susceptibili

213 The ECVs (expressed as mug/ml) for fluconazole, posaconazole, and voriconazole, respectivel

214 sons between the EUCAST and CLSI results for fluconazole, posaconazole, and voriconazole, respectivel

215 e activities of isavuconazole, itraconazole, fluconazole, posaconazole, voriconazole, and the three e

216 Fluconazole promotes collecting duct AQP2 plasma membran

217 Fluconazole prophylaxis appears to be well tolerated for

218 birth weight of less than 750 g, 42 days of fluconazole prophylaxis compared with placebo did not re

219 omized, placebo-controlled trials evaluating fluconazole prophylaxis in premature infants conducted i

220 Fluconazole prophylaxis is effective and safe in reducin

221 Fluconazole prophylaxis reduced the odds of IC or death,

222 Fluconazole prophylaxis reduces candidiasis, but its eff

223 Limiting fluconazole prophylaxis to infants with risk factors, in

224 xis (standard of care), 2) universal primary fluconazole prophylaxis, 3) CRAG screening with fluconaz

225 of invasive candidiasis may not benefit from fluconazole prophylaxis.

226 es (triazoles: cyproconazole, epoxiconazole, fluconazole, propiconazole, tebuconazole and imidazoles:

227 rAg) screening and treatment with preemptive fluconazole reduces the incidence of clinically evident

228 Prevalence of fluconazole resistance (7%) was unchanged compared with

229 death, IC, death, Candida colonization, and fluconazole resistance among tested isolates.

230 There was no change in the proportion of fluconazole resistance between surveillance periods.

231 Fluconazole resistance in C. albicans, C. tropicalis, an

232 patients increased the overall percentage of fluconazole resistance to 16%.

233 Increased fluconazole resistance was also observed in mutants lack

234 High levels of fluconazole resistance were detected, while few isolates

235 Importantly, although all isolates were fluconazole resistant in vitro, fluconazole and voricona

236 ant C. glabrata isolates from 2011, 38% were fluconazole resistant.

237 was highly active in vitro against numerous fluconazole-resistant clinical isolates of C. albicans a

238 isolates, 4 to 7 fluconazole-susceptible or fluconazole-resistant isolates from each of 5 center A p

239 ocandin-resistant strains detected among 110 fluconazole-resistant isolates of C. glabrata tested in

240 0.1-2.0 microg/ml and was also inhibitory to fluconazole-resistant isolates of Candida species.

241 There were 18 fluconazole-resistant isolates that were resistant to on

242 e or more of the echinocandins (11.1% of all fluconazole-resistant isolates), all of which contained

243 term and long-term toxicity and increases in fluconazole-resistant organisms have not been observed w

244 ities were hypokalemia (22 caspofungin vs 13 fluconazole), respiratory failure (6 caspofungin vs 9 fl

245 , prophylaxis with caspofungin compared with fluconazole resulted in significantly lower incidence of

246 fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the u

247 Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a si

248 We also tested fluconazole's effects on water flow across epithelia of

249 hotericin B (0.7-1.0 mg/kg per day) and oral fluconazole (starting at 800 mg/day) with either adjunct

250 antial difference in lipogenesis between the fluconazole-susceptible and -resistant C. albicans.

251 g to probe for metabolic differences between fluconazole-susceptible and -resistant strains at a sing

252 epidemiologically unrelated isolates, 4 to 7 fluconazole-susceptible or fluconazole-resistant isolate

253 h of 5 center A patients, 5 matched pairs of fluconazole-susceptible/resistant isolates from center B

254 A promising fluconazole-synergizing anticholinergic drug, dicyclomin

255 Among infants receiving fluconazole, the composite primary end point of death or

256 tolerance of Cryptococcus neoformans towards fluconazole, the widely used drug for treatment of crypt

257 treated with fluconazole and the duration of fluconazole therapy for each infant.

258 and 5.7% (95% CI, 3.0%-9.7%) with preemptive fluconazole therapy initiated at 800 mg/d.

259 bicans infection by administering antifungal fluconazole therapy protected the animals from systemic

260 rough cost and scarcity of registration; and fluconazole through challenges in maintenance of local s

261 onazole and was reduced by L-NMMA and L-NMMA+fluconazole to a lesser extent than in controls.

262 s, as well as a new mechanism of suppressing fluconazole toxicity by repression of the ERG25 gene.

263 h CD4<100 cells/mcL who received pre-emptive fluconazole treatment (CRAG+ cohort) and 189 ART-naive U

264 Pre-ART CRAG screening with preemptive fluconazole treatment and improved CM treatment(s) are n

265 Fluconazole treatment decreased mucosal injury but faile

266 se reports suggest that long-term, high-dose fluconazole treatment for severe fungal infections durin

267 conazole prophylaxis, 3) CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG scree

268 Fluconazole treatment in utero decreased intestinal C.al

269 egy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive individuals.

270 of individuals initiating ART and preemptive fluconazole treatment of CrAg-positive patients resulted

271 ation of CUTS and to compare echinocandin to fluconazole treatment on CUTS outcomes.

272 Upon fluconazole treatment, Mpk1, the downstream target of PK

273 re given intra-amniotic and intra-peritoneal fluconazole treatments 2 days after intra-amniotic admin

274 independent, and positive association of the fluconazole trough concentration with the fluconazole do

275 This review will describe the history of fluconazole use for prophylaxis in infants.

276 bility was independently associated with any fluconazole use in the 3 months prior to the IFI, C. gla

277 istant organisms have not been observed with fluconazole use in the intensive care nursery.

278 malignancy (odds ratio [OR], 5.09, P = .01), fluconazole use within 30 days prior to voriconazole (OR

279 n January 2012 and May 2013 for agreement of fluconazole, voriconazole, and amphotericin B susceptibi

280 The clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have be

281 ties of 1,669 BSI isolates of C. glabrata to fluconazole, voriconazole, anidulafungin, caspofungin, a

282 antifungal drugs that are used systemically (fluconazole, voriconazole, ketoconazole, itraconazole, a

283 nst seven antifungal agents (amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, an

284 the comparison, 130 of 2823 women exposed to fluconazole vs 118 of 2823 exposed to topical azoles had

285 CI, 1.26-2.07]); 20 of 4301 women exposed to fluconazole vs 22 of 4301 exposed to topical azoles had

286 int in infants who received prophylaxis with fluconazole vs placebo was compared.

287 Overall susceptibility to fluconazole was 79.2%.

288 Resistance to fluconazole was low among the isolates of C. albicans (0

289 Oral fluconazole was not associated with a significantly incr

290 Fluconazole was not effective against preformed mixed- C

291 A survival benefit of amphotericin B plus fluconazole was not found.

292 ng the compounds tested, the first-line drug fluconazole was the weakest inhibitor, whereas posaconaz

293 C. glabrata (11.9% resistant), resistance to fluconazole was very low (2.3% of isolates for C. albica

294 he PCs except acesulfame, carbamazepine, and fluconazole were attenuated along the studied river stre

295 Filled prescriptions for oral fluconazole were obtained from the National Prescription

296 nhibitory concentration of amphotericin B or fluconazole when used in combination with those antifung

297 eptibility of clinically important yeasts to fluconazole when using the new (lower) CBPs and ECVs.

298 Fluconazole, which is currently used for PAM therapy, wa

299 may have been due to increased resistance to fluconazole, which may have developed during the chronic

300 e whether combining flucytosine or high-dose fluconazole with high-dose amphotericin B improved survi